Stryker Corporation $SYK Shares Acquired by Bogart Wealth LLC

Bogart Wealth LLC increased its holdings in shares of Stryker Corporation (NYSE:SYK) by 1.1% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 11,292 shares of the medical technology company’s stock after purchasing an additional 127 shares during the quarter. Bogart Wealth LLC’s holdings in Stryker were worth $4,467,000 at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. Sachetta LLC lifted its holdings in shares of Stryker by 58.7% in the 2nd quarter. Sachetta LLC now owns 73 shares of the medical technology company’s stock worth $29,000 after acquiring an additional 27 shares during the last quarter. Goodman Advisory Group LLC purchased a new stake in Stryker in the first quarter valued at approximately $32,000. Ridgewood Investments LLC lifted its stake in Stryker by 48.4% during the second quarter. Ridgewood Investments LLC now owns 92 shares of the medical technology company’s stock worth $36,000 after purchasing an additional 30 shares in the last quarter. Ransom Advisory Ltd purchased a new position in shares of Stryker during the first quarter worth $37,000. Finally, Smallwood Wealth Investment Management LLC acquired a new stake in shares of Stryker in the first quarter valued at $40,000. Institutional investors and hedge funds own 77.09% of the company’s stock.

Insider Activity

In other news, Director Ronda E. Stryker sold 200,000 shares of the company’s stock in a transaction dated Wednesday, August 6th. The stock was sold at an average price of $376.45, for a total transaction of $75,290,000.00. Following the completion of the transaction, the director directly owned 3,222,108 shares of the company’s stock, valued at approximately $1,212,962,556.60. This represents a 5.84% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Viju Menon sold 500 shares of the firm’s stock in a transaction dated Monday, August 25th. The stock was sold at an average price of $390.61, for a total value of $195,305.00. Following the sale, the insider directly owned 12,511 shares in the company, valued at $4,886,921.71. This trade represents a 3.84% decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 5.20% of the company’s stock.

Stryker Stock Up 1.5%

Shares of Stryker stock opened at $374.67 on Monday. The company has a quick ratio of 1.06, a current ratio of 1.78 and a debt-to-equity ratio of 0.70. Stryker Corporation has a 52-week low of $329.16 and a 52-week high of $406.19. The company has a market capitalization of $143.24 billion, a P/E ratio of 49.63, a P/E/G ratio of 2.70 and a beta of 0.94. The company has a 50 day moving average of $379.40 and a 200 day moving average of $378.85.

Stryker (NYSE:SYK) last announced its quarterly earnings data on Thursday, July 31st. The medical technology company reported $3.13 EPS for the quarter, beating analysts’ consensus estimates of $3.07 by $0.06. The company had revenue of $6.02 billion for the quarter, compared to the consensus estimate of $5.92 billion. Stryker had a net margin of 12.25% and a return on equity of 23.94%. The company’s quarterly revenue was up 11.1% compared to the same quarter last year. During the same period in the prior year, the firm posted $2.81 EPS. Stryker has set its FY 2025 guidance at 13.400-13.600 EPS. As a group, research analysts forecast that Stryker Corporation will post 13.47 EPS for the current fiscal year.

Stryker Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, October 31st. Shareholders of record on Tuesday, September 30th will be issued a dividend of $0.84 per share. This represents a $3.36 dividend on an annualized basis and a yield of 0.9%. The ex-dividend date of this dividend is Tuesday, September 30th. Stryker’s payout ratio is 44.50%.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on the company. Weiss Ratings reissued a “buy (b-)” rating on shares of Stryker in a research note on Wednesday, October 8th. Rothschild Redb raised shares of Stryker to a “hold” rating in a research report on Thursday, September 18th. Wells Fargo & Company raised their price objective on shares of Stryker from $435.00 to $445.00 and gave the company an “overweight” rating in a research note on Friday, August 1st. Truist Financial cut their target price on shares of Stryker from $415.00 to $407.00 and set a “hold” rating on the stock in a research note on Wednesday. Finally, Wall Street Zen upgraded shares of Stryker from a “hold” rating to a “buy” rating in a report on Saturday. Fifteen equities research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $431.76.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.